FDA Approves Protalix BioTherapeutics's Phase III Clinical Study

Armen Hareyan's picture
Advertisement

Protalix BioTherapeutics's Phase III Clinical Study

Protalix BioTherapeutics has reached an agreement with FDA on the final design of its pivotal phase III clinical trial for its lead product candidate, prGCD, through the FDA's Special Protocol Assessment

Advertisement